Please assess the completion status of the following clinical trial:

Trial Title: A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.~* The participant has a history of migraine onset at least 12 months prior to the Screening Visit.~* The participant has a migraine onset at ≤50 years of age.~* The participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications.~Key Exclusion Criteria:~* The participant has been previously dosed with an anti-pituitary adenylate cyclase-activating polypeptide (anti-PACAP) ligand-targeting antibody.~* The participant has confounding and clinically significant pain syndromes.~* The participant has a diagnosis of acute or active temporomandibular disorder.~* The participant has a history or diagnosis of confounding headaches.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lu AG09222 High Dose (Type: EXPERIMENTAL): Participants will receive a single high dose of Lu AG09222 by intravenous (IV) infusion.
- Lu AG09222 Low Dose (Type: EXPERIMENTAL): Participants will receive a single low dose of Lu AG09222 by IV infusion.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a single dose of placebo matching to Lu AG09222 by IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).